{"identifier":"/us/usc/t21/s379aa","title_num":"21","num":"§ 379aa.","heading":"Serious adverse event reporting for nonprescription drugs","status":null,"guid":"ide4ed6a17-ec7d-11e6-944b-93361b188886","source_credit":"(June 25, 1938, ch. 675, § 760, as added Pub. L. 109–462, § 2(a), Dec. 22, 2006, 120 Stat. 3469.)","seq_in_title":307,"parent_identifier":"/us/usc/t21/ch9/schVII/ptH","ancestors":[{"identifier":"/us/usc/t21","level":"title","num":"Title 21—","heading":"FOOD AND DRUGS","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch9","level":"chapter","num":"CHAPTER 9—","heading":"FEDERAL FOOD, DRUG, AND COSMETIC ACT","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch9/schVII","level":"subchapter","num":"SUBCHAPTER VII—","heading":"GENERAL AUTHORITY","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch9/schVII/ptH","level":"part","num":"Part H—","heading":"Serious Adverse Event Reports","status":null,"is_section":false}],"xml":"<section xmlns=\"http://xml.house.gov/schemas/uslm/1.0\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dc=\"http://purl.org/dc/elements/1.1/\" xmlns:dcterms=\"http://purl.org/dc/terms/\" style=\"-uslm-lc:I80\" id=\"idae7848a0-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa\"><num value=\"379aa\">§ 379aa.</num><heading> Serious adverse event reporting for nonprescription drugs</heading><subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae7848a1-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a\"><num value=\"a\" class=\"bold\">(a)</num><heading class=\"bold\"> Definitions</heading><chapeau>In this section:</chapeau><paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848a2-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/1\"><num value=\"1\" class=\"bold\">(1)</num><heading class=\"bold\"> Adverse event</heading><chapeau>The term “adverse event” means any health-related event associated with the use of a nonprescription drug that is adverse, including—</chapeau><subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae7848a3-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/1/A\"><num value=\"A\">(A)</num><content> an event occurring from an overdose of the drug, whether accidental or intentional;</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae7848a4-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/1/B\"><num value=\"B\">(B)</num><content> an event occurring from abuse of the drug;</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae7848a5-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/1/C\"><num value=\"C\">(C)</num><content> an event occurring from withdrawal from the drug; and</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae7848a6-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/1/D\"><num value=\"D\">(D)</num><content> any failure of expected pharmacological action of the drug.</content>\n</subparagraph>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848a7-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/2\"><num value=\"2\" class=\"bold\">(2)</num><heading class=\"bold\"> Nonprescription drug</heading><chapeau>The term “nonprescription drug” means a drug that is—</chapeau><subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae7848a8-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/2/A\"><num value=\"A\">(A)</num><content> not subject to <ref href=\"/us/usc/t21/s353/b\">section 353(b) of this title</ref>; and</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae7848a9-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/2/B\"><num value=\"B\">(B)</num><content> not subject to approval in an application submitted under <ref href=\"/us/usc/t21/s355\">section 355 of this title</ref>.</content>\n</subparagraph>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848aa-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/3\"><num value=\"3\" class=\"bold\">(3)</num><heading class=\"bold\"> Serious adverse event</heading><chapeau>The term “serious adverse event” is an adverse event that—</chapeau><subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae7848ab-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/3/A\"><num value=\"A\">(A)</num><chapeau> results in—</chapeau><clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae7848ac-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/3/A/i\"><num value=\"i\">(i)</num><content> death;</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae7848ad-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/3/A/ii\"><num value=\"ii\">(ii)</num><content> a life-threatening experience;</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae7848ae-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/3/A/iii\"><num value=\"iii\">(iii)</num><content> inpatient hospitalization;</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae7848af-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/3/A/iv\"><num value=\"iv\">(iv)</num><content> a persistent or significant disability or incapacity; or</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae7848b0-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/3/A/v\"><num value=\"v\">(v)</num><content> a congenital anomaly or birth defect; or</content>\n</clause>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae7848b1-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/3/B\"><num value=\"B\">(B)</num><content> requires, based on reasonable medical judgment, a medical or surgical intervention to prevent an outcome described under subparagraph (A).</content>\n</subparagraph>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848b2-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/a/4\"><num value=\"4\" class=\"bold\">(4)</num><heading class=\"bold\"> Serious adverse event report</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">The term “serious adverse event report” means a report that is required to be submitted to the Secretary under subsection (b).</p>\n</content>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae7848b3-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/b\"><num value=\"b\" class=\"bold\">(b)</num><heading class=\"bold\"> Reporting requirement</heading><paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848b4-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/b/1\"><num value=\"1\" class=\"bold\">(1)</num><heading class=\"bold\"> In general</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">The manufacturer, packer, or distributor whose name (pursuant to <ref href=\"/us/usc/t21/s352/b/1\">section 352(b)(1) of this title</ref>) appears on the label of a nonprescription drug marketed in the United States (referred to in this section as the “responsible person”) shall submit to the Secretary any report received of a serious adverse event associated with such drug when used in the United States, accompanied by a copy of the label on or within the retail package of such drug.</p>\n</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848b5-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/b/2\"><num value=\"2\" class=\"bold\">(2)</num><heading class=\"bold\"> Retailer</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">A retailer whose name appears on the label described in paragraph (1) as a distributor may, by agreement, authorize the manufacturer or packer of the nonprescription drug to submit the required reports for such drugs to the Secretary so long as the retailer directs to the manufacturer or packer all adverse events associated with such drug that are reported to the retailer through the address or telephone number described in <ref href=\"/us/usc/t21/s352/x\">section 352(x) of this title</ref>.</p>\n</content>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae7848b6-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/c\"><num value=\"c\" class=\"bold\">(c)</num><heading class=\"bold\"> Submission of reports</heading><paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848b7-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/c/1\"><num value=\"1\" class=\"bold\">(1)</num><heading class=\"bold\"> Timing of reports</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">The responsible person shall submit to the Secretary a serious adverse event report no later than 15 business days after the report is received through the address or phone number described in <ref href=\"/us/usc/t21/s352/x\">section 352(x) of this title</ref>.</p>\n</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848b8-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/c/2\"><num value=\"2\" class=\"bold\">(2)</num><heading class=\"bold\"> New medical information</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">The responsible person shall submit to the Secretary any new medical information, related to a submitted serious adverse event report that is received by the responsible person within 1 year of the initial report, no later than 15 business days after the new information is received by the responsible person.</p>\n</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848b9-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/c/3\"><num value=\"3\" class=\"bold\">(3)</num><heading class=\"bold\"> Consolidation of reports</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">The Secretary shall develop systems to ensure that duplicate reports of, and new medical information related to, a serious adverse event shall be consolidated into a single report.</p>\n</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848ba-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/c/4\"><num value=\"4\" class=\"bold\">(4)</num><heading class=\"bold\"> Exemption</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">The Secretary, after providing notice and an opportunity for comment from interested parties, may establish an exemption to the requirements under paragraphs (1) and (2) if the Secretary determines that such exemption would have no adverse effect on public health.</p>\n</content>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae7848bb-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/d\"><num value=\"d\" class=\"bold\">(d)</num><heading class=\"bold\"> Contents of reports</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">Each serious adverse event report under this section shall be submitted to the Secretary using the MedWatch form, which may be modified by the Secretary for nonprescription drugs, and may be accompanied by additional information.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae7848bc-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/e\"><num value=\"e\" class=\"bold\">(e)</num><heading class=\"bold\"> Maintenance and inspection of records</heading><paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848bd-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/e/1\"><num value=\"1\" class=\"bold\">(1)</num><heading class=\"bold\"> Maintenance</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">The responsible person shall maintain records related to each report of an adverse event received by the responsible person for a period of 6 years.</p>\n</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848be-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/e/2\"><num value=\"2\" class=\"bold\">(2)</num><heading class=\"bold\"> Records inspection</heading><subparagraph style=\"-uslm-lc:I18\" class=\"indent4 firstIndent-2\" id=\"idae7848bf-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/e/2/A\"><num value=\"A\" class=\"bold\">(A)</num><heading class=\"bold\"> In general</heading><content><p style=\"-uslm-lc:I13\" class=\"indent2\">The responsible person shall permit an authorized person to have access to records required to be maintained under this section, during an inspection pursuant to <ref href=\"/us/usc/t21/s374\">section 374 of this title</ref>.</p>\n</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I18\" class=\"indent4 firstIndent-2\" id=\"idae7848c0-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/e/2/B\"><num value=\"B\" class=\"bold\">(B)</num><heading class=\"bold\"> Authorized person</heading><chapeau>For purposes of this paragraph, the term “authorized person” means an officer or employee of the Department of Health and Human Services who has—</chapeau><clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae7848c1-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/e/2/B/i\"><num value=\"i\">(i)</num><content> appropriate credentials, as determined by the Secretary; and</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae7848c2-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/e/2/B/ii\"><num value=\"ii\">(ii)</num><content> been duly designated by the Secretary to have access to the records required under this section.</content>\n</clause>\n</subparagraph>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae7848c3-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/f\"><num value=\"f\" class=\"bold\">(f)</num><heading class=\"bold\"> Protected information</heading><chapeau>A serious adverse event report submitted to the Secretary under this section, including any new medical information submitted under subsection (c)(2), or an adverse event report voluntarily submitted to the Secretary shall be considered to be—</chapeau><paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"idae7848c4-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/f/1\"><num value=\"1\">(1)</num><content> a safety report under <ref href=\"/us/usc/t21/s379v\">section 379v of this title</ref> and may be accompanied by a statement, which shall be a part of any report that is released for public disclosure, that denies that the report or the records constitute an admission that the product involved caused or contributed to the adverse event; and</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"idae7848c5-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/f/2\"><num value=\"2\">(2)</num><content> a record about an individual under <ref href=\"/us/usc/t5/s552a\">section 552a of title 5</ref> (commonly referred to as the “Privacy Act of 1974”) and a medical or similar file the disclosure of which would constitute a violation of section 552 of such title 5 (commonly referred to as the “Freedom of Information Act”), and shall not be publicly disclosed unless all personally identifiable information is redacted.</content>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae7848c6-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/g\"><num value=\"g\" class=\"bold\">(g)</num><heading class=\"bold\"> Rule of construction</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">The submission of any adverse event report in compliance with this section shall not be construed as an admission that the nonprescription drug involved caused or contributed to the adverse event.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae7848c7-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/h\"><num value=\"h\" class=\"bold\">(h)</num><heading class=\"bold\"> Preemption</heading><paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848c8-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/h/1\"><num value=\"1\" class=\"bold\">(1)</num><heading class=\"bold\"> In general</heading><content><p style=\"-uslm-lc:I12\" class=\"indent1\">No State or local government shall establish or continue in effect any law, regulation, order, or other requirement, related to a mandatory system for adverse event reports for nonprescription drugs, that is different from, in addition to, or otherwise not identical to, this section.</p>\n</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae7848c9-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/h/2\"><num value=\"2\" class=\"bold\">(2)</num><heading class=\"bold\"> Effect of section</heading><subparagraph style=\"-uslm-lc:I18\" class=\"indent4 firstIndent-2\" id=\"idae7848ca-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/h/2/A\"><num value=\"A\" class=\"bold\">(A)</num><heading class=\"bold\"> In general</heading><content><p style=\"-uslm-lc:I13\" class=\"indent2\">Nothing in this section shall affect the authority of the Secretary to provide adverse event reports and information to any health, food, or drug officer or employee of any State, territory, or political subdivision of a State or territory, under a memorandum of understanding between the Secretary and such State, territory, or political subdivision.</p>\n</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I18\" class=\"indent4 firstIndent-2\" id=\"idae7848cb-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/h/2/B\"><num value=\"B\" class=\"bold\">(B)</num><heading class=\"bold\"> Personally-identifiable information</heading><chapeau>Notwithstanding any other provision of law, personally-identifiable information in adverse event reports provided by the Secretary to any health, food, or drug officer or employee of any State, territory, or political subdivision of a State or territory, shall not—</chapeau><clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae7848cc-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/h/2/B/i\"><num value=\"i\">(i)</num><content> be made publicly available pursuant to any State or other law requiring disclosure of information or records; or</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae7848cd-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/h/2/B/ii\"><num value=\"ii\">(ii)</num><content> otherwise be disclosed or distributed to any party without the written consent of the Secretary and the person submitting such information to the Secretary.</content>\n</clause>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I18\" class=\"indent4 firstIndent-2\" id=\"idae7848ce-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/h/2/C\"><num value=\"C\" class=\"bold\">(C)</num><heading class=\"bold\"> Use of safety reports</heading><content><p style=\"-uslm-lc:I13\" class=\"indent2\">Nothing in this section shall permit a State, territory, or political subdivision of a State or territory, to use any safety report received from the Secretary in a manner inconsistent with subsection (g) or <ref href=\"/us/usc/t21/s379v\">section 379v of this title</ref>.</p>\n</content>\n</subparagraph>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae7848cf-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s379aa/i\"><num value=\"i\" class=\"bold\">(i)</num><heading class=\"bold\"> Authorization of appropriations</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">There are authorized to be appropriated to carry out this section such sums as may be necessary.</p>\n</content>\n</subsection>\n<sourceCredit id=\"idae7848d0-ec38-11e5-9fc5-818d616f3d7f\">(<ref href=\"/us/act/1938-06-25/ch675\">June 25, 1938, ch. 675</ref>, § 760, as added <ref href=\"/us/pl/109/462\">Pub. L. 109–462</ref>, § 2(a), <date date=\"2006-12-22\">Dec. 22, 2006</date>, <ref href=\"/us/stat/120/3469\">120 Stat. 3469</ref>.)</sourceCredit>\n<notes type=\"uscNote\" id=\"idae7848d1-ec38-11e5-9fc5-818d616f3d7f\">\n<note style=\"-uslm-lc:I74\" topic=\"effectiveDate\" id=\"idae7848d2-ec38-11e5-9fc5-818d616f3d7f\"><heading class=\"centered smallCaps\">Effective Date</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">Section effective 1 year after <date date=\"2006-12-22\">Dec. 22, 2006</date>, see <ref href=\"/us/pl/109/462/s2/e/1\">section 2(e)(1) of Pub. L. 109–462</ref>, set out as an Effective Date of 2006 Amendment note under <ref href=\"/us/usc/t21/s352\">section 352 of this title</ref>.</p>\n</note>\n<note style=\"-uslm-lc:I74\" topic=\"miscellaneous\" id=\"idae7848d3-ec38-11e5-9fc5-818d616f3d7f\"><heading class=\"centered smallCaps\">Modifications</heading><p><ref href=\"/us/pl/109/462\">Pub. L. 109–462</ref>, § 2(b), <date date=\"2006-12-22\">Dec. 22, 2006</date>, <ref href=\"/us/stat/120/3472\">120 Stat. 3472</ref>, provided that: <quotedContent origin=\"/us/pl/109/462\">“The Secretary of Health and Human Services may modify requirements under the amendments made by this section [enacting this section and amending sections 331 and 352 of this title] in accordance with <ref href=\"/us/usc/t5/s553\">section 553 of title 5</ref>, United States Code, to maintain consistency with international harmonization efforts over time.”</quotedContent>\n</p>\n</note>\n<note style=\"-uslm-lc:I74\" topic=\"miscellaneous\" id=\"idae7848d4-ec38-11e5-9fc5-818d616f3d7f\"><heading class=\"centered smallCaps\">Guidance</heading><p><ref href=\"/us/pl/109/462\">Pub. L. 109–462</ref>, § 2(e)(3), <date date=\"2006-12-22\">Dec. 22, 2006</date>, <ref href=\"/us/stat/120/3472\">120 Stat. 3472</ref>, provided that: <quotedContent origin=\"/us/pl/109/462\">“Not later than 270 days after the date of enactment of this Act [<date date=\"2006-12-22\">Dec. 22, 2006</date>], the Secretary of Health and Human Services shall issue guidance on the minimum data elements that should be included in a serious adverse event report described under the amendments made by this Act [see Short Title of 2006 Amendment note set out under <ref href=\"/us/usc/t21/s301\">section 301 of this title</ref>].”</quotedContent>\n</p>\n<p style=\"-uslm-lc:I21\" class=\"indent0\"><ref href=\"/us/pl/109/462\">Pub. L. 109–462</ref>, § 3(d)(3), <date date=\"2006-12-22\">Dec. 22, 2006</date>, <ref href=\"/us/stat/120/3475\">120 Stat. 3475</ref>, enacted provisions substantially identical to those enacted by <ref href=\"/us/pl/109/462\">Pub. L. 109–462</ref>, § 2(b), set out above.</p>\n</note>\n</notes>\n</section>","provision":null,"duplicates":[],"release":{"label":"114-321","currency_date":"2016-12-16","congress":114,"law_num":321,"excluded_laws":[],"update_num":null,"seq":88,"is_partial":false,"caveat":null,"titles_affected":["05","15","21","26","28","29","38","42","48"],"ingested_titles":[]},"served_from":{"label":"114-321","currency_date":"2016-12-16","congress":114,"law_num":321,"excluded_laws":[],"update_num":null,"seq":88,"is_partial":false,"caveat":null,"titles_affected":["05","15","21","26","28","29","38","42","48"],"ingested_titles":[]},"content_first_seen":{"label":"114-115","currency_date":"2015-12-28","congress":114,"law_num":115,"excluded_laws":[],"update_num":null,"seq":62,"is_partial":false,"caveat":null,"titles_affected":["02","07","08","10","15","20","21","23","25","26","29","31","40","42","47","49","50"],"ingested_titles":[]},"is_exact":true,"note":null}